Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency
David J. Snodin,Alejandra Trejo-Martin,David J. Ponting,Graham F. Smith,Andreas Czich,Kevin Cross,Laura Custer,Joanne Elloway,Nigel Greene,Amit S. Kalgutkar,Susanne A. Stalford,Rachael E. Tennant,Esther Vock,Adam Zalewski,Verena Ziegler,Krista L. Dobo
DOI: https://doi.org/10.1021/acs.chemrestox.3c00327
2024-02-05
Chemical Research in Toxicology
Abstract:A thorough literature review was undertaken to understand how the pathways of <i>N</i>-nitrosamine transformation relate to mutagenic potential and carcinogenic potency in rodents. Empirical and computational evidence indicates that a common radical intermediate is created by CYP-mediated hydrogen abstraction at the α-carbon; it is responsible for both activation, leading to the formation of DNA-reactive diazonium species, and deactivation by denitrosation. There are competing sites of CYP metabolism (e.g., β-carbon), and other reactive species can form following initial bioactivation, although these alternative pathways tend to decrease rather than enhance carcinogenic potency. The activation pathway, oxidative dealkylation, is a common reaction in drug metabolism and evidence indicates that the carbonyl byproduct, e.g., formaldehyde, does not contribute to the toxic properties of <i>N</i>-nitrosamines. Nitric oxide (NO), a side product of denitrosation, can similarly be discounted as an enhancer of <i>N</i>-nitrosamine toxicity based on carcinogenicity data for substances that act as NO-donors. However, not all <i>N</i>-nitrosamines are potent rodent carcinogens. In a significant number of cases, there is a potency overlap with non-<i>N</i>-nitrosamine carcinogens that are not in the Cohort of Concern (CoC; high-potency rodent carcinogens comprising aflatoxin-like-, <i>N</i>-nitroso-, and alkyl-azoxy compounds), while other <i>N</i>-nitrosamines are devoid of carcinogenic potential. In this context, mutagenicity is a useful surrogate for carcinogenicity, as proposed in the ICH M7 (R2) (2023) guidance. Thus, in the safety assessment and control of <i>N</i>-nitrosamines in medicines, it is important to understand those complementary attributes of mechanisms of mutagenicity and structure-activity relationships that translate to elevated potency versus those which are associated with a reduction in, or absence of, carcinogenic potency.
chemistry, medicinal,toxicology, multidisciplinary